ClinicalTrials.gg
CompletedNCT04969978CONNECTUpdated Oct 21, 2026Results posted

Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation

An interventional study of Enhanced Academic Detailing and Informational Intervention in Tobacco-Related Carcinoma and Smoking &Amp; Tobacco Cessation, sponsored by OHSU Knight Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Prevention

How we know

Updated Oct 21, 2026Now CompletedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9,133
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.

Enrollment
7th of 785
9,133 · median 109
Started
2023
with 25 others
No phase
494 of 899
59 open now
Registered
728th of 899
by date

Among the 899 studies in Smoking with a site in United States, this one is the 7th largest by enrollment of the 785 interventional ones that give a count, is one of 26 that started in 2023, is one of 494 with no phase, and was the 728th registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 899 studies in Smoking with a site in United States, or all of them as a file.
02

Study summary

This phase IV clinical trial determines the impact of implementing a Quitline electronic (e)Referral system with an enhanced academic detailing implementation strategy on Quitline reach, tobacco cessation assistance and self-reported quit rates among patients in community health centers. It also examines the cost-effectiveness of Quitline eReferrals both with and without enhanced academic detailing. If this implementation strategy is effective, this strategy could be used to increase tobacco cessation treatment through the collaboration between state Quitlines and community health centers that serve large numbers of socioeconomically disadvantaged patients who use tobacco.

Read the detailed description

PRIMARY OBJECTIVES:

I. Implement a Quitline electronic (e)Referral system with enhanced academic detailing (AD) (intervention; n=10 community health centers [CHCs]) and without enhanced AD (comparison; n=10 CHCs) to compare rates of eReferral offers, eReferral acceptance, Quitline enrollment, orders for tobacco cessation medication, and receipt of in-clinic counseling among patients identified as currently using tobacco.

II. Assess the effectiveness of implementing a Quitline eReferral system with enhanced AD (intervention) versus without enhanced AD (comparison) on self-reported tobacco quit rates among all patients identified as current persons using tobacco using electronic health record (EHR) data.

III. Estimate the total annual costs and incremental cost-effectiveness of a Quitline eReferral system, with and without enhanced AD.

OUTLINE: Clinics are randomized to 1 of 2 arms.

ARM I: Clinics are notified via email that the eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding electronic health record (EHR) screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.

ARM II: Clinics receive standard online materials and access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the Quitline eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.

03

Conditions studied

  • Tobacco-Related Carcinoma
  • Smoking &Amp; Tobacco Cessation
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Study Clinic Inclusion Criteria:

  • In Oregon
  • On the OCHIN Epic EHR for >= 1 year
  • Willing to be randomized to the intervention or comparison condition
  • Willing to recruit a provider to serve as a clinic champion (to share monthly performance audit and feedback at all-staff meetings, determine desired content of booster sessions with clinic team members, and complete a survey at the completion of the intervention period) and a clinic manager to coordinate training and booster sessions

Study Patient Inclusion Criteria:

  • Adult patients (>= 18 years of age)
  • Identified as current tobacco users during >= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 26-month study period
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9,133 participants (actual)

Study arms

  • Active comparator
    Arm I (Quitline eReferral)

    Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.

    Other: Informational Intervention

  • Experimental
    ARM II (Quitline eReferral plus enhanced AD)

    Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.

    Behavioral: Enhanced Academic Detailing · Other: Informational Intervention

Interventions

  • BehavioralEnhanced Academic Detailing

    * Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation * Follow-up booster sessions * Monthly performance audit and feedback

    Also known as: EAD

  • OtherInformational Intervention

    Receive overview of Quitline services and use of Quitline eReferral via online materials

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Accepted Electronic (e)Referral to Quitline

    Number of patients who accepted a Quitline eReferral in intervention (EAD) versus comparator clinics among those using tobacco.

    Time frame: At any point during the 26-month intervention period

Secondary outcomes

  1. Quitline eReferral Offered

    Number of patients who were offered the Quitline eReferral.

    Time frame: At any point during the 26-month intervention period

  2. Quitline Enrollment

    Number of patients who accepted the Quitline eReferral and enrolled in Quitline services.

    Time frame: At any point during the 26-month intervention period

  3. Receipt of In-office Counseling

    Number of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit.

    Time frame: At any point during the 26-month intervention period

  4. Tobacco Cessation Medication Ordered

    Number of patients with a tobacco cessation medication in the 'medication orders' list of the EHR.

    Time frame: At any point during the 26-month intervention period

  5. Tobacco Cessation

    Number of patients with EHR status change from current to former tobacco use.

    Time frame: At any point during the 26-month intervention period or up to 6 months post-intervention

  6. Annual Intervention Costs

    Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.

    Time frame: Years 1-4

  7. Cost-effectiveness

    Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.

    Time frame: Years 1-4

07

Results

Posted Oct 21, 2026

Participant flow

Recruited clinics affiliated with OCHIN in Oregon. Clinics had ≥300 unique patients; ≥ 1 patient identified as smoking; \<50% private insurance. Eligible individuals are aged ≥ 18 years and noted as currently using tobacco at any time during the study.

Participant flow — Overall Study
MilestoneArm I (Quitline eReferral)ARM II (Quitline eReferral Plus Enhanced AD)
Started46444489
Completed46444489
Not completed00

Outcome measures

PrimaryNumber of Participants Who Accepted Electronic (e)Referral to Quitline

Number of patients who accepted a Quitline eReferral in intervention (EAD) versus comparator clinics among those using tobacco.

Time frame:
At any point during the 26-month intervention period
Reported as:
Count of participants · Participants
Number of Participants Who Accepted Electronic (e)Referral to Quitline
ParticipantsArm I (Quitline eReferral)ARM II (Quitline eReferral Plus Enhanced AD)
Number of Participants Who Accepted Electronic (e)Referral to Quitline264420
SecondaryQuitline eReferral Offered

Number of patients who were offered the Quitline eReferral.

Time frame:
At any point during the 26-month intervention period

Results for this outcome have not been posted.

SecondaryQuitline Enrollment

Number of patients who accepted the Quitline eReferral and enrolled in Quitline services.

Time frame:
At any point during the 26-month intervention period

Results for this outcome have not been posted.

SecondaryReceipt of In-office Counseling

Number of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit.

Time frame:
At any point during the 26-month intervention period

Results for this outcome have not been posted.

SecondaryTobacco Cessation Medication Ordered

Number of patients with a tobacco cessation medication in the 'medication orders' list of the EHR.

Time frame:
At any point during the 26-month intervention period

Results for this outcome have not been posted.

SecondaryTobacco Cessation

Number of patients with EHR status change from current to former tobacco use.

Time frame:
At any point during the 26-month intervention period or up to 6 months post-intervention

Results for this outcome have not been posted.

SecondaryAnnual Intervention Costs

Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.

Time frame:
Years 1-4

Results for this outcome have not been posted.

SecondaryCost-effectiveness

Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.

Time frame:
Years 1-4

Results for this outcome have not been posted.

Adverse events

Collected over From enrollment until end of data collection (26 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (Quitline eReferral)0/4,644 (0%)0/4,644 (0%)0/4,644 (0%)
ARM II (Quitline eReferral Plus Enhanced AD)0/4,489 (0%)0/4,489 (0%)0/4,489 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm I (Quitline eReferral)ARM II (Quitline eReferral Plus Enhanced AD)Total
<=18 years363167
Between 18 and 65 years404638947940
>=65 years5625641126
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Arm I (Quitline eReferral)ARM II (Quitline eReferral Plus Enhanced AD)Total
Sex — Female200620884094
Sex — Male263824015039
Sex — Other000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (Quitline eReferral)ARM II (Quitline eReferral Plus Enhanced AD)Total
American Indian or Alaska Native6480144
Asian14048188
Native Hawaiian or Other Pacific Islander000
Black or African American197218415
White365035137163
More than one race171118289
Unknown or Not Reported422512934
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I (Quitline eReferral)ARM II (Quitline eReferral Plus Enhanced AD)Total
Hispanic or Latino430428858
Not Hispanic or Latino380335237326
Unknown or Not Reported411538949
08

Study locations

1 site
  • OHSU Knight Cancer Institute
    Portland, Oregon 97239, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Limited data set was given by partner research organization under data use agreement that excludes disclosure of any data outside of this study.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2025, 26 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 405 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 26 months is close to that.

Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
Jul 21, 2021
StartActual
Jun 20, 2023
Primary completionActual
Aug 22, 2025
CompletionActual
Feb 22, 2026
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 21, 2026
Results
Results posted
posted Oct 21, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedIdentified as current tobacco users during >= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 2426-month study period
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants Who Accepted electronicElectronic (e)Referral to QuitlineTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
Oct 21, 2026
Secondary outcomes
6 edited, 2 removed
What changed in the outcomes
  • EditedQuitline eReferral offeredOfferedTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
  • EditedQuitline enrollmentEnrollmentTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
  • EditedReceipt of inIn-office counselingCounselingTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
  • EditedTobacco cessation medication orderedCessation Medication OrderedTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
  • EditedTobacco cessationCessationTime frame: At any point during the 24-month intervention period or up to 6 months post-intervention → At any point during the 26-month intervention period or up to 6 months post-intervention
  • EditedAnnual intervention costsIntervention CostsTime frame: Years 1-4
  • RemovedIncremental cost-effectiveness ratioTime frame: Years 1-4
  • Removedother outcomeTobacco use assessedTime frame: At any point during the 24-month intervention period
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Completed
    Results posted
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedIdentified as current tobacco users during >= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 2426-month study period
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants Who Accepted electronicElectronic (e)Referral to QuitlineTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
    Secondary outcomes 6 edited, 2 removed
    What changed in the outcomes
    • EditedQuitline eReferral offeredOfferedTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
    • EditedQuitline enrollmentEnrollmentTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
    • EditedReceipt of inIn-office counselingCounselingTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
    • EditedTobacco cessation medication orderedCessation Medication OrderedTime frame: At any point during the 24-month intervention period → At any point during the 26-month intervention period
    • EditedTobacco cessationCessationTime frame: At any point during the 24-month intervention period or up to 6 months post-intervention → At any point during the 26-month intervention period or up to 6 months post-intervention
    • EditedAnnual intervention costsIntervention CostsTime frame: Years 1-4
    • RemovedIncremental cost-effectiveness ratioTime frame: Years 1-4
    • Removedother outcomeTobacco use assessedTime frame: At any point during the 24-month intervention period
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04969978
Responsible party
Steffani Bailey (Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Jul 21, 2021
Start date
Jun 20, 2023
Primary completion
Aug 22, 2025
Completion
Feb 22, 2026
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Steffani Bailey
principal investigator · OHSU Department of Family Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion